Abstract Hybrid cardiac single photon emission computed tomography (SPECT)/CT imaging allows combined assessment of anatomical and functional aspects of cardiac disease. In coronary artery disease (CAD), hybrid SPECT/CT imaging allows detection of coronary artery stenosis and myocardial perfusion abnormalities. The clinical value of hybrid imaging has been documented in several subsets of patients. In selected groups of patients, hybrid imaging improves the diagnostic accuracy to detect CAD compared to the single imaging techniques. Additionally, this approach facilitates functional interrogation of coronary stenoses and guidance with regard to revascularization procedures. Moreover, the anatomical information obtained from CT coronary angiography or coronary artery calcium scores (CACS) adds prognostic information over perfusion data from SPECT. The use of cardiac hybrid imaging has been favoured by the dissemination of dedicated hybrid systems and the release of dedicated image fusion software, which allow simple patient throughput for hybrid SPECT/CT studies. Further technological improvements such as more efficient detector technology to allow for low-radiation protocols, ultra-fast image acquisition and improved low-noise image reconstruction algorithms will be instrumental to further promote hybrid SPECT/CT in research and clinical practice.
Introduction
Non-invasive cardiac imaging has witnessed tremendous advances in the last few decades. This holds true particularly for techniques to detect coronary artery disease (CAD) which are currently used for the diagnosis, prognostication and risk stratification of patients with known or suspected CAD. As a result, the number of non-invasive cardiac imaging tests has steadily increased over the last few years [1] . This has driven the dissemination of state-of-the art high-end devices for computed tomography (CT) and nuclear cardiology worldwide.
Besides morphological CAD, functional consequences of coronary stenoses on myocardial perfusion and metabolism are relevant. Additionally, other entities such as microvascular or endothelial dysfunction have been recognized to contribute significantly to disease pathology [2, 3] . Hence, clinical cardiac imaging is increasingly challenged to address in a comprehensive manner the anatomical and functional aspects of CAD in order to provide guidance for appropriate medical or interventional therapies.
Hybrid imaging has achieved increasing clinical acceptance because it provides anatomical information on the presence of coronary artery lesions combined with functional information on its pathophysiological consequences with regard to myocardial perfusion or metabolism. The present review provides an overview on the most important clinical aspects of cardiac single photon emission computed tomography (SPECT)/CT hybrid imaging touching upon the clinical need and the technical requirements. We provide an overview of relevant literature highlighting the clinical value and addressing potential indications and pitfalls of cardiac hybrid imaging. Finally, as research is ongoing and the technique is continuously expanding to other indications we will provide a glimpse into potential future clinical avenues of hybrid imaging.
Clinical background
There is poor agreement between the degree of stenosis of a coronary lesion and the presence of myocardial ischaemia. A number of studies using intraoperative Doppler ultrasound, positron emission tomography (PET) and fractional flow reserve (FFR) have consistently demonstrated that the angiographic severity of coronary lesions is a poor predictor of its haemodynamic relevance [4] [5] [6] [7] . Similarly, comparative studies of CT coronary angiography (CTCA) and myocardial perfusion imaging (MPI) showed that only 30-50 % of stenoses with more than 50 % luminal narrowing are associated with reversible perfusion defects on MPI, and conversely many patients with completely normal myocardial perfusion may harbour subclinical CAD [8] [9] [10] [11] .
Large randomized clinical trials have failed to demonstrate superiority of revascularization over modern medical treatment in terms of long-term cardiovascular events if patients are not stratified by prior ischaemia testing [12, 13] . Reducing the ischaemic burden of the left ventricular (LV) myocardium seems to improve the outcome of stable CAD patients [14, 15] . The pivotal role of ischaemia-targeted revascularization has further been highlighted in the randomized FAME I trial [16] . Finally, the FAME II trial has proven-for the first time in a prospective randomized study-superiority of revascularization over optimal medical treatment for patients with flowlimiting coronary stenoses (FFR <0.80) [17] . Similar large prospective randomized trials with non-invasive imaging instead of FFR are currently enrolling patients [18] . Consequently, tests for myocardial ischaemia are incorporated into current revascularization guidelines, beyond the assessment of coronary morphology alone [19] .
Thus, functional interrogation of coronary lesions is feasible with FFR during invasive coronary angiography and has gained wide acceptance based on the solid evidence published in favour of the technique. However, a non-invasive anatomical and functional assessment of CAD should be preferred as first-line test in the majority of patients with suspected CAD in order to reduce procedure-related morbidity and costs [20] . CT FFR was recently developed as a method to determine haemodynamic relevance of coronary lesions from standard CT angiograms using computational fluid dynamics. This technique is still experimental and a recent study has shown limitations of this technique in routine clinical practice [21] .
CT coronary angiography
Accuracy for detection of coronary artery stenosis
The diagnostic performance of CTCA as compared to invasive coronary angiography has been documented in various studies [22] and recently also in meta-analyses [23] . The latter revealed a pooled area under the receiver-operating characteristic curve of 0.99 for diameter stenoses >50 %. Pooled sensitivity and specificity were 99 and 89 %, respectively [24, 25] . The available data consistently document excellent diagnostic performance of CTCA for identifying and ruling out coronary artery stenoses >50 % when compared to invasive coronary angiography.
Early studies on CTCA reported effective radiation dose levels up to 20 mSv when using spiral acquisitions with retrospective ECG gating. However, current radiation dose levels are far lower, owing to the development and application of sequential and high-pitch scans [26] as well as to the use of lower tube voltage settings and iterative reconstructions [27] . Currently, effective radiation dose levels of CTCA are in the range of 1-5 mSv. Given the more widespread application of CTCA with increasing numbers of examinations worldwide, this dose reduction is important for patient safety, particularly if hybrid imaging protocols are considered.
While robustness and stability of CTCA continues to improve with each CT technology development, giving rise to improved temporal and spatial resolution in in vitro studies [28] and a reduction of image noise when using iterative reconstructions [29] , CTCA still does not perform well at high and irregular heart rates, in morbidly obese patients, in patients with stents and in cases of severe coronary calcifications. Each of these features may result in a non-diagnostic CTCA study, precluding its application in these patients.
Plaque detection and characterization
Being a cross-sectional imaging modality, CTCA depicts the coronary wall including plaques in addition to stenoses. Most studies so far have focused on a simple categorization scheme of coronary plaques as non-calcified, partially calcified and calcified. By doing so, authors found a good agreement between CTCA and intravascular ultrasound representing the clinical reference standard modality for plaque characterization. Still, this current way of plaque classification based on CTCA falls short of a more advanced description of plaque characteristics, such as the identification of thin-cap fibroatheromas which are believed to represent late stage and potentially vulnerable coronary plaques. Recently, Maurovich-Horvat and colleagues described in their in vitro studies a "napkin-ring" sign plaque in coronary arteries, representing a ring of hyperattenuation surrounding a low attenuating centre [30] . This plaque type was highly predictive of thin-cap fibroatheroma as determined by histopathology [30] [31] [32] . Interestingly, a recent in vivo study demonstrated that the napkin-ring sign plaque depicted with CTCA was strongly associated with future acute coronary syndrome events, being independent of other high-risk coronary CTCA features [33] . While these recent studies are highly promising, the current clinical role of coronary plaque characterization with CTCA has still not been defined. Further improvements in spatial and contrast resolution are required for a better anatomical depiction and differentiation of the various plaque types.
Myocardial perfusion SPECT
Myocardial perfusion can be assessed using radionuclide imaging studies such as SPECT or (in more specialized centres) PET. With SPECT a vast amount of data is available demonstrating its excellent diagnostic accuracy for detecting angiographically significant CAD with a sensitivity and specificity of 87-89 % and 73-75 %, respectively, depending on the choice of radionuclide and stress modality [34] . Gated SPECT offers information of LV volumes and ejection fraction. A large body of evidence documents the prognostic value of SPECT with a consistent <1 % cardiac event rate for patients with completely normal perfusion on SPECT [35] . Current software packages allow semiquantitative assessment of perfusion defect extent in relation to the total LV myocardium. Based on these quantitative measures of ischaemic burden, SPECT has demonstrated its value for guiding revascularization procedures in CAD patients [15, 19, 36] . In patients with ischaemia extending over ≥10 % of the left ventricle, a revascularization procedure improves the outcome, while in patients with <10 % medical therapy is equivalent or better. Finally, SPECT provides three-dimensional (3-D) data sets as CTCA (in DICOM). These data sets can be easily superimposed onto CT images (after correcting for the lower matrix size and bigger voxel size) using dedicated fusion software.
Again, radiation exposure is a concern, particularly with SPECT and SPECT/CT. However, low-dose SPECT is feasible with novel solid-state detector cameras and improved iterative image reconstruction algorithms with effective radiation doses in the range of 4-7 mSv [37, 38] . Further reduction to <2 mSv is achievable if stress protocols are performed first and rest images are not required. Other functional modalities [stress echocardiography, stress cardiac magnetic resonance imaging (CMR)] are potentially attractive candidates for hybrid imaging. Both modalities avoid ionizing radiation; however, the two-dimensional image format of echocardiograms is unsuitable for fusion with CTCA. Stress CMR/ CTCA fusion may be possible using fast perfusion sequences and is currently under clinical investigation [39] [40] [41] .
Hybrid systems
The first hybrid devices were PET/CT tomographs which gained wide acceptance in oncology for the staging of neoplastic disease. Along this path, similar hybrid devices combining SPECT cameras with high-end CT devices and recently also first experimental hybrid PET/MR have been released. Figure 1 gives an overview of commercially available hybrid SPECT/CT devices from different manufacturers. Some of these devices offer attractive features for hybrid imaging. The Discovery NM/CT 570c consists of a small footprintdedicated cardiac SPECT camera equipped with solid-state semiconductor detector technology and multi-pinhole collimators. This novel assembly combined with the unique geometry results in an exceptionally high photon sensitivity [37] . It allows shortened acquisition times to 5 min or less [42] and thereby improves patient comfort and throughput for hybrid imaging. The Siemens Symbia TruePoint System is equipped with intelligent collimators that track and centre the heart to improve count sensitivity. The AnyScan SPECT/CT system from Mediso Medical Imaging Systems (Budapest, Hungary) is equipped with a 16-slice CT and can be upgraded to a SPECT/PET/CT hybrid system. The majority of these hybrid devices are available with high-end CT devices; however, it should be emphasized that for coronary CT angiography the recommended minimum number of slices is 64. CT machines having less slices have a temporal and spatial resolution that is not high enough to provide a diagnostic image quality of all coronary segments in a sufficient number of patients.
The majority of novel SPECT/CT systems offer improved image reconstruction techniques [37] : These novel algorithms are largely based on modelling the specific geometry of the detectors and the collimator to improve count sensitivity. Furthermore, most systems offer compensation for image resolution loss by accelerated iterative reconstruction. Several manufacturers have taken this approach [e.g. wide beam reconstruction (WBR) by UltraSpect Ltd., Haifa, Israel; Astonish by Philips, Best, The Netherlands; IQ SPECT by Siemens, Erlangen, Germany; and Evolution by GE Healthcare, Milwaukee, WI, USA]. With these improved reconstruction techniques, further reductions in image acquisition times or radiation may be achieved [43] .
Post-processing and image analysis software
In the setting of cardiac hybrid imaging the use of hybrid systems is not necessarily required and less important than for oncology whole-body PET/CT. Nonetheless, in cardiac SPECT/CT imaging, manual superposition and individual correction of data set misalignment is crucial to ensure adequate quality for several reasons: cardiac and respiratory motion, intrinsic disagreement in the size and shape of the left ventricle between non-gated SPECT images (unfortunately gated SPECT images are too noisy for hybrid imaging) and diastole-gated CTCA and 3-D instead of cross-sectional display of fused data sets. Therefore, cardiac hybrid imaging can easily be performed by acquiring data sets on stand-alone systems with subsequent software-based fusion, and in fact this set-up may allow exploitation of the full capacity of the respective systems for all kinds of medical purposes rather than having a highly dedicated hybrid device.
Dedicated software packages are available from different manufacturers/research institutions that allow fusion of CTCA and radionuclide images (Fig. 2) [44] . A crucial element is a user interface that permits correction of misalignment between data sets. The remaining fusion steps include tracking of the coronary arteries (by the same methods as standard CTCA software) and modelling of the perfusion data into a 3-D volume rendering of the left ventricle. Current software packages allow fusion of images from different modalities and even different manufacturers. In experienced hands and with image data sets of reasonable quality, the image fusion process takes no longer than 5 min per patient. Additional reconstruction tools that eliminate the influence of cardiac LV motion in the display and freeze myocardial perfusion information in a diastolic frame ("motion-frozen" technique) may further facilitate image fusion [45] . Table 1 shows a summary of available diagnostic studies with cardiac hybrid imaging. The feasibility and clinical robustness of non-invasive hybrid imaging was first documented by Namdar and co-workers in a clinical study involving fusion of 13 N-NH 3 PET with 4-slice CTCA in 25 patients with CAD [46] . These encouraging results were replicated with SPECT/ CT in a study by Rispler and co-workers who documented an increase in specificity (from 63 to 95 %) and positive predictive value (PPV, from 31 to 77 %) with SPECT/CTCA compared to CTCA alone [47] . Sato and co-workers showed that adding SPECT information in non-evaluable arteries on CTCA improved particularly specificity and PPV significantly (from 80 to 92 % and from 69 to 85 %, respectively) [48] . Notably, the majority of non-evaluable severely calcified vessels in the left anterior descending artery were positive on stress nuclear MPI, whereas the majority of non-evaluable vessels with motion artefacts in the right coronary artery were negative. One of the largest, recently published studies included 107 patients undergoing hybrid 15 O-H 2 O PET/64-slice CTCA [49] . In this study, haemodynamic significance of coronary stenoses was confirmed in 18 of 40 patients with FFR providing a more comprehensive gold standard. Consequently, the use of PET/CTCA increased the PPV significantly from 76 to 96 % compared to CTCA alone.
Clinical value of hybrid imaging
However, a number of limitations apply to the aforementioned studies including the limited number of patients, the variety of hybrid systems used and the lack of a uniform gold standard. Three studies have specifically addressed the incremental value of hybrid cardiac imaging over the sideby-side analysis of CTCA and myocardial perfusion images (Table 2) in patients with multivessel disease (MVD), intermediate severity coronary stenoses and/or side branch disease [45, 50, 51] . Hence, hybrid cardiac imaging may facilitate the identification of haemodynamically significant coronary artery stenoses and thereby guide clinicians on the appropriate method of revascularization. Moreover, in intermediate stenoses, a hybrid study may accurately confirm or rule out their haemodynamic significance and thereby reduce the number of A recent study including more than 500 patients has also documented the prognostic value of hybrid imaging [52] . In this study, CTCA stenoses provided independent prognostic information over SPECT alone. Moreover, the presence of non-calcified plaque emerged as an independent predictor along with CTCA stenoses and abnormal SPECT. Further Fig. 2 The main steps of SPECT/CT image fusion (CardIQ Fusion, Advantage Workstation, GE Healthcare). a Image coregistration. This first step is crucial and allows the user to align the images on axial, sagittal and coronal image planes in order to obtain optimal matching of structural and functional information. b Definition of LV epicardium. This protocol displays a view containing the segmented CT LVepicardium using the conventional volume rendering technique, allowing addition or removal of structures from the LV epicardium if needed. In each point of the surface of the volume rendered image the colour is computed as being the maximum perfusion intensity on a ray going from the particular point to the centre of the heart on CT. c Coronary tree segmentation. This protocol allows the user to grow the coronary arteries from the ascending aorta using automatic vessel tracking or manual segmentation. d 3-D volume rendered fusion images. As the final step, the hybrid display protocol displays a volume rendering containing the LV epicardial volume, the volume rendered coronary tree, and the left and right heart chambers acquired by an automatic segmentation algorithm. (Reprinted with permission from Springer [44] ) n number of patients in each study, SPECT single photon emission computed tomography, CTCA CT coronary angiography, PET positron emission tomography, CAD coronary artery disease, Sens sensitivity, Spec specificity, PPV positive predictive value, NPV negative predictive value, ICA invasive coronary angiography, FFR fractional flow reserve a Hybrid SPECT/CTCA only applied for non-evaluable arteries on CTCA (14 %) prognostic information is provided by the spatial superposition of perfusion defects and coronary CT stenosis [53] . In this study, 324 consecutive patients undergoing hybrid SPECT/ CTCA were subdivided into three groups: (1) stenosis by CTCA and matching reversible SPECT defect (i.e. the perfusions defect was superimposed on the stenotic coronary artery on the hybrid 3-D display), (2) unmatched CTCA and SPECT finding and (3) normal finding by CTCA and SPECT. On follow-up (median 2.8 years), a corresponding matched hybrid finding was associated with a significantly higher event rate [death or myocardial infarction (MI)] and proved to be an independent predictor for major adverse cardiovascular events (MACE). The annual death/MI rate was 6.0, 2.8 and 1.3 % for patients with matched, unmatched and normal findings. Two further studies have proven that hybrid imaging has an impact on downstream resource utilization and most notably on revascularization rates. Pazhenkottil et al. reported that revascularization rates within 60 days were 41, 11 and 0 % for matched, unmatched and normal findings, respectively (p <0.001) [54] . In a similar study by Schaap and colleagues, revascularization rates were even higher with 90, 31 and 0 % for matched, unmatched and normal findings, respectively (p <0.001) [55] . These results should be highlighted in the context of the recent SPARC study which documented a surprisingly modest impact of stand-alone non-invasive imaging modalities on downstream resource utilization with 38-61 % of patients with the most severe abnormalities on CTCA or perfusion scans not being referred for invasive angiography [56] . Thus, it appears that the combined anatomical and functional assessment of CAD by hybrid imaging may encourage guideline-concordant patient management among physicians ordering those tests.
Clinical indications for hybrid imaging
Open questions remain as to which patients benefit from integrated hybrid imaging. It appears that the vast majority of patients referred for non-invasive cardiac imaging studies to exclude or confirm the presence of CAD are adequately addressed with one single study (i.e. either CTCA or functional imaging test). Additionally, the increased radiation and higher costs of hybrid imaging studies have to be considered as an important factor. Therefore, patients should be carefully selected where an added value of hybrid imaging may be anticipated.
Intermediate pretest likelihood
The pretest likelihood of CAD can be assessed based on the age and gender of the subject, the typicality of chest pain and the ECG changes on exercise testing [57] . Patients with intermediate pretest likelihood are more likely to yield intermediate or inconclusive results in one of the imaging studies, e.g. intermediate coronary stenosis on CTCA. In this situation, an additional perfusion study may address the haemodynamic relevance of such lesions and help to decide whether the patient can be treated medically or needs to be referred for invasive angiography with revascularization. Such sequential hybrid imaging protocols have been implemented in several centres with hybrid imaging capabilities. However, beta blockers given prior to the CTCA study may affect the subsequent SPECT study by blunting perfusion defect extent and reversibility, and vasodilator stress protocols should be preferred over exercise or dobutamine whenever the CTCA study precedes the SPECT [58, 59] . Likewise, CT tomographs having a high temporal resolution obviating the need for beta blocker administration prior to the imaging study are preferred.
Multivessel disease
Patients with MVD represent a population that is at increased risk for future cardiac events and therefore is often referred for revascularization to improve outcomes. However, the majority of patients with angiographic three-vessel disease turn out to have considerably less flow-limiting lesions than suspected from their angiograms [7] . Compared to perfusion imaging alone, hybrid imaging may have an incremental diagnostic value to identify haemodynamically significant lesions particularly in patients with MVD ( Fig. 3 ) [51] . By this means, hybrid imaging may allow targeted revascularization procedures in MVD patients avoiding stent or bypass overuse with the inherent adverse sequelae of stent or graft reocclusion.
Significant side branch disease
Side branches are often regarded as prognostically insignificant but may be associated with significant angina. Although perfusion defects in side branch disease are generally smaller, they may be difficult to distinguish from main branch disease. Hybrid imaging provides accurate coregistration of coronary anatomy and perfusion defects and therefore allows identifcation of flow-limiting lesions in side branches (diagonal, posterolateral branches) for targeted revascularization procedures [50] (Fig. 4) .
Chronic total occlusions
Percutaneous revascularization procedures in patients with chronic total occlusions (CTO) are associated with higher rates of complications and larger contrast media and radiation administration. Therefore, proof of myocardial ischaemia in the territory of the occluded vessel is mandatory prior to embarking on any potentially harmful intervention. On the one hand, hybrid imaging may accurately detect a perfusion defect located in the territory of the CTO vessel. On the other hand, anatomical CT information such as the morphology of the stump, the presence of side vessels, the length of occlusion and/or calcifications or the presence of tortuosity are predictors A B C D E Fig. 3 Example of a 59-year-old gentleman with three-vessel disease who underwent stenting of the right coronary artery a few months prior to his hybrid SPECT/CT study. Angiography revealed a long 80 % stenosis of the mid left anterior descending artery and a 70 % stenosis of the proximal left circumflex artery (LCX) which was confirmed on CTCA (yellow arrows, c).
SPECT showed a partially reversible perfusion defect (white arrows) of the inferolateral wall (a stress, b rest). On hybrid SPECT/CT, the inferolateral ischaemia could be localized to the LCX (e, arrows), while the anterior wall did not show any relevant perfusion defect (d). This indicates that treatment should be targeted to the LCX to reduce ischaemic burden of the LV myocardium of procedural success and may help to decide between anterograde or retrograde revascularization approaches [60] .
Hybrid imaging for attenuation correction
The quality and accuracy of nuclear perfusion studies is often affected by non-uniform photon attenuation, a common source of image artefacts with often unpredictable patterns. Tc have been proposed but yielded ambiguous results [61] .
CT has shown promising results for attenuation correction of SPECT allowing consistent image reading [62, 63] . The radiation emitted from X-ray CT tubes is polychromatic compared to the monoenergetic gamma photons from a radioactive line source. Also, the flux of photons from a typical X-ray tube is much higher than a conventional sealed radioactive source. As a result transmission images for attenuation correction can be obtained within seconds using CT. However, some pitfalls of CT-based attenuation correction should be considered. For example, misalignment between SPECT and the attenuation map can lead to artefacts in the apical, septal and anterior walls that will appear as defects. It also can cause overcorrection in the basal inferior and lateral segments. There is evidence that mismatches along the other directions may have a similar effect.
Although in SPECT photon energies are lower (70 keV  with   210   Tl and 140 keV with   99m Tc versus 511 keV with positron-emitting radionuclides) and thus more susceptible to attenuation, the pattern of attenuation is less predictable than with PET. Therefore, with SPECT, the use of X-raybased attenuation correction is less well established. As a result, most current dedicated cardiac SPECT systems are not equipped with a low-dose CT facility for attenuation correction. This can be overcome by using low-dose native coronary artery calcium score (CACS) scans performed on a stand-alone high-end CT device for attenuation correction of the SPECT images. In contrast to present low-dose CT facilities of hybrid SPECT/CT systems, CACS scans are ECGtriggered and acquired during a single breath-hold. Hence, this approach requires the use of interface software for manual coregistration of SPECT and CT information to avoid misalignment between both images (Fig. 5) . The feasibility and reproducibility of this method has been demonstrated by Schepis and co-workers using CACS scans during full inspiratory and expiratory breath-hold [64] . Parametric attenuation A B C D Fig. 4 maps from CACS scans provided accurate and reliable attenuation correction of SPECT images resulting in a very good correlation compared to the established attenuation correction with the low-dose low-resolution CT facility included in the hybrid SPECT/CT system.
Added value of CACS over SPECT alone
CACS provides an estimate of coronary atherosclerotic plaque burden and correlates strongly with the overall amount of coronary plaque (calcified and non-calcified) seen in postmortem examinations [65] . Assessment of the presence of subclinical coronary atherosclerosis with CACS provides an opportunity to identify asymptomatic patients who are at risk for developing clinical CAD over the long term. Several studies in asymptomatic subjects have consistently shown that CACS provides accurate risk estimates for cardiac death and ischaemic events beyond clinical parameters [66, 67] . These observations have led to the implementation of CACS in current recommendations for coronary risk assessment [68, 69] . Particularly in patients at intermediate clinical risk, CACS may prove helpful in more accurate risk stratification [70] . In addition to its prognostic value, CACS may also offer diagnostic information. Coronary artery calcifications are almost always present with angiographically significant CAD; thus, a CACS of 0 virtually excludes any significant angiographic CAD [71] , particularly in asymptomatic patients. However, specificity and PPV (23-62 %) are low and increase only moderately when shifting the CACS cut-off from 0 to higher values. While CACS is rarely used as a diagnostic test for CAD detection, combined protocols with SPECT may be attractive through integration of anatomical and functional information. In a recent study by Schepis and colleagues the combination of SPECT and CACS resulted in a significant improvement in sensitivity and specificity for the diagnosis of angiographically significant CAD compared to SPECT alone [9] . The presence of high atherosclerotic burden in a symptomatic patient with a normal or near-normal perfusion scan should alert the reader to the possibility of MVD and a potential underestimation of jeopardized myocardium by SPECT alone [72] . On the other hand, an equivocal perfusion result in the presence of zero CACS may raise the suspicion of an attenuation or respiratory artefact justifying further CTCA to rule out CAD.
CACS may also add prognostic information to MPI. Schenker and colleagues observed an independent stepwise increase in death and MI rates with increasing CACS in 695 consecutive patients regardless of the presence or absence of ischaemia on perfusion scan [73] . Among patients with normal perfusion, the annualized event rate in patients with a CACS of 0 was 2.6 % versus 12.3 % in those with a CACS ≥1,000. Likewise, in patients with ischaemia, the annualized event rate in those with a CACS of 0 was lower than among patients with a CACS ≥1,000 (8.2 versus 22.1 %). Similar results were obtained in 510 asymptomatic patients, albeit at a lower CACS cut-off of 100 [74] . These results were not confirmed in a similar study performed in 1,153 very low-risk patients undergoing SPECT and CACS with short follow-up [75] . Chang and colleagues reported an incremental prognostic value of CACS in 977 asymptomatic patients with normal SPECT perfusion scans and a follow-up of 6.9 years [76] . There was a 3.6-fold relative increase for any cardiac event and a 2.8-fold relative increase for death/MI when the CACS was severe (>400) versus minimal (≤10). Separation of the survival curves occurred at 3 years after initial testing for all cardiac events and at 5 years for death/MI. This indicates that if CACS is severe the "warranty period" of a normal SPECT expires after 3-5 years. The REPROSPECT registry revealed the added prognostic value of fusing CACS and myocardial perfusion SPECT to allocate calcified vessels to their respective vascular territories [77] . Patients were divided into three groups (1) MPI defect matched by calcification (CAC≥1) in the subtending coronary artery, (2) unmatched MPI and CT finding and (3) normal finding by MPI and CT. At the 35-month follow-up, the most unfavourable outcome was observed in patients with matched findings (36 versus 16 % in the group with unmatched findings versus 0 % in the normal group, p <0.001) (Fig. 6 ).
Perspectives of hybrid imaging
Hybrid imaging is increasingly contributing to the development of imaging strategies which go beyond the assessment of myocardial perfusion. Furthermore, the use of other modalities (e.g. cardiac MRI) may expand existing indications for hybrid imaging. A number of novel hybrid imaging approaches hold promise to make their way into clinical practice or are already being used in very specialized centres.
Cardiac resynchronization therapy (CRT) has established itself as an important therapeutic option to improve symptoms and prognosis in heart failure patients. Unfortunately, CRT non-responder rates are still high (approximately 30 %), particularly in patients with ischaemic heart disease. Therefore, efficient tools to predict CRT success and improve patient selection are urgently needed. Hybrid imaging may combine venous anatomy from CT (by scanning in the venous phase) with viability information from SPECT. This approach may allow visualization of venous morphology and identification of candidate veins for percutaneous lead insertion, while at the same time viability in this territory is ascertained [78] . It is likely that patients in whom the LV lead is placed in a nonviable territory may not respond to CRT. Furthermore, mechanical LV dyssynchrony can be quantified by phase analysis of gated perfusion SPECT studies [79] . Potentially, this approach could prove useful to optimize CRT.
Experimental approaches in human and animal studies have used hybrid imaging to colocalize anatomical information with (mainly radionuclide) signals from molecular pathways that precede or underlie changes in morphology or pathophysiology. Examples are the use of neuronal imaging to identify subjects at risk for ventricular arrhythmia, the development of compounds targeting plaque vulnerability before rupture and subsequent MI, the targeting of biomechanisms which precede LV remodelling and heart failure development, the development of reporter gene imaging techniques and the implementation of cell labelling for imaging of engraftment after transplantation [80, 81] .
Conclusion
A comprehensive appraisal of anatomical and functional aspects of disease is crucial in cardiac imaging, particularly for the appropriate management of patients with known or suspected CAD. Hybrid imaging has entered the clinical arena in the past few decades and is facing increasing interest for clinical and research purposes as it allows one to obtain combined anatomical and functional information of cardiac pathology through non-invasive multimodality imaging. Hybrid SPECT/CT imaging is promoted by the dissemination of hybrid devices, the development of improved devices and protocols with reduced radiation exposure and shorter acquisition times, and the implementation of efficient and dedicated image reconstruction and fusion algorithms. The combined anatomical and functional information on CAD extent and severity may facilitate diagnosis, improve risk stratification and guide appropriate management strategies (particularly by selecting patients that may benefit from revascularization procedures) in particular subsets of CAD patients. However, the added costs and increased radiation exposure of hybrid imaging studies must be considered before ordering such tests, and larger prospective studies are needed to address issues such as incremental clinical value, impact on patient management and outcome and cost-effectiveness. Nevertheless, the use of hybrid imaging in other fields of cardiology may enhance our pathophysiological understanding of cardiac pathologies by linking morphological changes with underlying biochemical or subsequent functional alterations and thereby open avenues for hybrid imaging in heart failure, CRT, stem cell and gene therapy, plaque imaging, cardiac remodelling and regenerative medicine.
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